0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Nonalcoholic fatty liver disease, liver fibrosis, and structural brain imaging: The Cross-Cohort Collaboration

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background and purpose:

          Prior studies reported conflicting findings regarding the association of nonalcoholic fatty liver disease (NAFLD) and liver fibrosis with measures of brain health. We examined whether NAFLD and liver fibrosis are associated with structural brain imaging measures in middle- and old-age adults.

          Methods:

          In this cross-sectional study among dementia- and stroke-free individuals, data were pooled from the Offspring and Third Generation cohorts of the Framingham Heart Study (FHS), the Rotterdam Study (RS), and the Study of Health in Pomerania. NAFLD was assessed through abdominal imaging. Transient hepatic elastography (FibroScan) was used to assess liver fibrosis in FHS and RS. Linear regression models were used to explore the relation of NAFLD and liver fibrosis with brain volumes, including total brain, gray matter, hippocampus, and white matter hyperintensities, adjusting for potential confounders. Results were combined using fixed effects meta-analysis.

          Results:

          In total, 5660 and 3022 individuals were included for NAFLD and liver fibrosis analyses, respectively. NAFLD was associated with smaller volumes of total brain (β = −3.5, 95% confidence interval [CI] = −5.4 to −1.7), total gray matter (β = −1.9, 95% CI = −3.4 to −0.3), and total cortical gray matter (β = −1.9, 95% CI = −3.7 to −0.01). In addition, liver fibrosis (defined as liver stiffness measure ≥8.2 kPa) was related to smaller total brain volumes (β = −7.3, 95% CI = −11.1 to −3.5). Heterogeneity between studies was low.

          Conclusions:

          NAFLD and liver fibrosis may be directly related to brain aging. Larger and prospective studies are warranted to validate these findings and identify liver-related preventive strategies for neurodegeneration.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

          Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes of NAFLD and nonalcoholic steatohepatitis (NASH). PubMed/MEDLINE were searched from 1989 to 2015 for terms involving epidemiology and progression of NAFLD. Exclusions included selected groups (studies that exclusively enrolled morbidly obese or diabetics or pediatric) and no data on alcohol consumption or other liver diseases. Incidence of hepatocellular carcinoma (HCC), cirrhosis, overall mortality, and liver-related mortality were determined. NASH required histological diagnosis. All studies were reviewed by three independent investigators. Analysis was stratified by region, diagnostic technique, biopsy indication, and study population. We used random-effects models to provide point estimates (95% confidence interval [CI]) of prevalence, incidence, mortality and incidence rate ratios, and metaregression with subgroup analysis to account for heterogeneity. Of 729 studies, 86 were included with a sample size of 8,515,431 from 22 countries. Global prevalence of NAFLD is 25.24% (95% CI: 22.10-28.65) with highest prevalence in the Middle East and South America and lowest in Africa. Metabolic comorbidities associated with NAFLD included obesity (51.34%; 95% CI: 41.38-61.20), type 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertension (39.34%; 95% CI: 33.15-45.88), and metabolic syndrome (42.54%; 95% CI: 30.06-56.05). Fibrosis progression proportion, and mean annual rate of progression in NASH were 40.76% (95% CI: 34.69-47.13) and 0.09 (95% CI: 0.06-0.12). HCC incidence among NAFLD patients was 0.44 per 1,000 person-years (range, 0.29-0.66). Liver-specific mortality and overall mortality among NAFLD and NASH were 0.77 per 1,000 (range, 0.33-1.77) and 11.77 per 1,000 person-years (range, 7.10-19.53) and 15.44 per 1,000 (range, 11.72-20.34) and 25.56 per 1,000 person-years (range, 6.29-103.80). Incidence risk ratios for liver-specific and overall mortality for NAFLD were 1.94 (range, 1.28-2.92) and 1.05 (range, 0.70-1.56).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Non-alcoholic fatty liver disease

            Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease continuum from steatosis with or without mild inflammation (non-alcoholic fatty liver), to non-alcoholic steatohepatitis (NASH), which is characterised by necroinflammation and faster fibrosis progression than non-alcoholic fatty liver. NAFLD has a bidirectional association with components of the metabolic syndrome, and type 2 diabetes increases the risk of cirrhosis and related complications. Although the leading causes of death in people with NAFLD are cardiovascular disease and extrahepatic malignancy, advanced liver fibrosis is a key prognostic marker for liver-related outcomes and overall mortality, and can be assessed with combinations of non-invasive tests. Patients with cirrhosis should be screened for hepatocellular carcinoma and oesophageal varices. There is currently no approved therapy for NAFLD, although several drugs are in advanced stages of development. Because of the complex pathophysiology and substantial heterogeneity of disease phenotypes, combination treatment is likely to be required for many patients with NAFLD. Healthy lifestyle and weight reduction remain crucial to the prevention and treatment of NAFLD.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

              We estimated the accuracy of FibroScan vibration-controlled transient elastography controlled attenuation parameter (CAP) and liver stiffness measurement (LSMs) in assessing steatosis and fibrosis in patients with suspected nonalcoholic liver disease (NAFLD).
                Bookmark

                Author and article information

                Journal
                9506311
                20870
                Eur J Neurol
                Eur J Neurol
                European journal of neurology
                1351-5101
                1468-1331
                15 September 2023
                January 2024
                28 August 2023
                05 February 2024
                : 31
                : 1
                : e16048
                Affiliations
                [1 ]School of Public Health, University of Haifa, Haifa, Israel
                [2 ]Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA
                [3 ]Framingham Study, Framingham, Massachusetts, USA
                [4 ]Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
                [5 ]Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands
                [6 ]Department of Radiology & Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
                [7 ]Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands
                [8 ]Neurosciences Laboratory, Biological Research Institute and Research Institute of Cardiovascular Diseases, Faculty of Medicine, Universidad del Zulia Maracaibo Venezuela, Maracaibo, Venezuela
                [9 ]Division of Neurosciences, Department of Biomedical Sciences, University of Texas Rio Grande Valley School of Medicine, Edinburg, Texas, USA
                [10 ]Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, Texas, USA
                [11 ]Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA
                [12 ]Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA
                [13 ]Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
                [14 ]Department of Medicine A, University Medicine Greifswald, Greifswald, Germany
                [15 ]Institute for Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany
                [16 ]Section of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
                [17 ]Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA
                [18 ]German Center for Neurodegenerative Disease, partner site Rostock/Greifswald, Rostock, Germany
                Author notes

                AUTHOR CONTRIBUTIONS

                Galit Weinstein: Conceptualization; writing–original draft; investigation; methodology; formal analysis. Adrienne O’Donnell: Writing–review & editing; formal analysis; conceptualization; methodology. Stefan Frenzel: Conceptualization; writing–review & editing; methodology; formal analysis. Tian Xiao: Writing–review & editing; conceptualization; formal analysis; methodology. Amber Yaqub: Conceptualization; writing–review & editing; formal analysis; methodology. Pinar Yilmaz: Data curation; conceptualization; writing–review & editing; methodology. Robert J. de Knegt: Conceptualization; writing–review & editing; methodology. Gladys E. Maestre: Conceptualization; methodology; writing–review & editing. Debora Melo van Lent: Conceptualization; writing–review & editing. Michelle Long: Conceptualization; writing–review & editing; methodology. Monica Gireud-Goss: Project administration; conceptualization. Till Ittermann: Conceptualization; writing–review & editing. Fabian Frost: Conceptualization; writing–review & editing. Robin Bülow: Conceptualization; writing–review & editing; data curation. Ramachandran S. Vasan: Conceptualization; writing–review & editing; methodology; resources; supervision. Hans J. Grabe: Resources; supervision; writing–review & editing; methodology; conceptualization. M. Arfan Ikram: Conceptualization; writing–review & editing; methodology; resources; supervision. Alexa S. Beiser: Conceptualization; investigation; writing–review & editing; methodology; software; formal analysis; data curation; supervision. Sudha Seshadri: Conceptualization; investigation; writing–review & editing; methodology; supervision; resources.

                Correspondence: Galit Weinstein, School of Public Health, University of Haifa, 199 Aba Khoushy Ave., Mount Carmel, Haifa 3498838, Israel. gweinstei@ 123456univ.haifa.ac.il
                Author information
                http://orcid.org/0000-0002-5711-2148
                http://orcid.org/0000-0002-3579-8054
                http://orcid.org/0000-0003-2393-3068
                Article
                NIHMS1931502
                10.1111/ene.16048
                10840827
                37641505
                55fce65f-ba2a-44bf-93f0-46b9cfee0bb2

                This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                Categories
                Article

                Neurology
                brain aging,brain mri,liver fibrosis,nonalcoholic fatty liver disease,observational study

                Comments

                Comment on this article